Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Pediatric access widens for rare immune disease therapies

Pediatric access widens for rare immune disease therapies

Rule Changes

FDA broadens ADMA's ASCENIV antibody therapy to children as young as two

May 4th, 2026: FDA approves ASCENIV for children aged 2 and older

Overview

For seven years, an immune therapy made from antibody-rich human plasma was available only to teenagers and adults. On May 4, 2026, the U.S. Food and Drug Administration extended ADMA Biologics' ASCENIV to children as young as two—closing a gap that left some of the most vulnerable pediatric patients dependent on off-label prescribing or alternative drugs.

The decision is one milestone in a quieter, continuous process: pediatric label expansions for rare-disease therapies that satisfy post-marketing study commitments tied to original approvals. For families managing primary humoral immunodeficiency—a condition where the body cannot produce enough antibodies to fight common infections—the change converts a treatment that doctors could only justify carefully into one with regulatory backing for routine use.

Why it matters

Young children with rare antibody deficiencies now have a specialized immune therapy approved for their age group, removing a longstanding gap in pediatric care.

Play on this story Voices Debate Predict

Key Indicators

Age 2
New minimum age
Lowered from 12, enabling earlier intervention for immune-compromised children.
1 in 500
U.S. primary immunodeficiency rate
Estimated prevalence of inherited immune disorders among Americans.
$363M
ASCENIV 2025 revenue
ADMA's specialty IVIG product grew 51% year-over-year before the pediatric label.
2019
Original approval
ASCENIV first approved for patients 12 and older with primary humoral immunodeficiency.
Lifelong
Typical treatment duration
Most patients with primary humoral immunodeficiency need antibody replacement for life.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Adam Grossman
Adam Grossman
Leading commercial expansion of ASCENIV into pediatrics
 Kaitlin Kestenberg
Kaitlin Kestenberg
Oversaw pediatric post-marketing study and sBLA filing

Organizations Involved

ADMA Biologics, Inc.
ADMA Biologics, Inc.
Biopharmaceutical Company
Manufacturer of ASCENIV; commercial beneficiary of label expansion

A vertically integrated specialty biologics company that collects plasma, manufactures immune globulin therapies, and markets them to immune-compromised patients.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Approved supplemental application expanding ASCENIV's pediatric indication

The federal agency that regulates biologic drugs, sets pediatric study requirements for new approvals, and reviews supplemental applications to expand product labels.

Timeline

  1. FDA approves ASCENIV for children aged 2 and older

    Regulatory

    The FDA approves the supplemental application, expanding ASCENIV to pediatric patients aged 2 to 11 and satisfying ADMA's pediatric post-marketing commitment.

  2. ADMA files pediatric sBLA

    Regulatory

    ADMA submits a supplemental biologics license application requesting expansion of the ASCENIV label to patients two years and older.

  3. Pediatric study database locked

    Clinical

    All pediatric patients enrolled in the post-marketing study complete their treatment schedules, and ADMA closes the database in preparation for the supplemental filing.

  4. FDA clears extended room-temperature storage

    Regulatory

    Storage flexibility for ASCENIV and BIVIGAM is broadened, simplifying logistics for home infusion and pediatric clinics that lack continuous cold-chain capacity.

  5. ASCENIV begins commercial sales

    Commercial

    ADMA Biologics names BioCareSD its primary distributor and reports first commercial sales of ASCENIV to specialty pharmacies and infusion providers.

  6. FDA approves ASCENIV for ages 12 and older

    Regulatory

    The FDA grants original approval for ASCENIV to treat primary humoral immunodeficiency in adults and adolescents, with a post-marketing commitment to study the drug in younger children.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

ASCENIV captures growing share of pediatric IVIG market

With on-label pediatric coverage, ADMA's sales force can market ASCENIV directly to pediatric immunologists and infusion centers. Insurance prior-authorization becomes more straightforward, shifting younger patients from generic IVIG products to ASCENIV's RSV-enriched formulation. Revenue acceleration from the $363 million 2025 base continues through 2027.

Discussed by: Sell-side biotech analysts covering ADMA; specialty pharmacy distributors
Consensus —
2

Subcutaneous immunoglobulin gains ground in young children

Some families and clinicians prefer subcutaneous immunoglobulin (SCIG) over intravenous products in young children because home administration is less invasive than monthly IV infusions. Even with the new label, ASCENIV's pediatric uptake may be tempered by SCIG products from competitors that already cover the same age group.

Discussed by: Pediatric immunologists; Immune Deficiency Foundation patient advocates
Consensus —
3

Plasma supply constraints throttle pediatric expansion

ASCENIV requires donors with high RSV antibody titers, a narrower pool than standard plasma. If demand from a broader pediatric population outpaces ADMA's specialized collection capacity, the company could face allocation decisions that limit how quickly the new indication translates into volume.

Discussed by: Industry trade publications covering plasma fractionation; ADMA management on earnings calls
Consensus —
4

Other IVIG manufacturers follow with pediatric label updates

ASCENIV is one of several IVIG products that originally carried adolescent-or-older labels. As post-marketing pediatric commitments come due across the category, additional manufacturers file similar supplemental applications, broadening competition and pressuring pricing in the pediatric segment.

Discussed by: Pharmacy Times; regulatory consultants tracking sBLA filings
Consensus —

Historical Context

Pediatric Research Equity Act passed (2003)

December 2003

What Happened

Congress made permanent the FDA's authority to require pediatric studies for new drugs and biologics likely to be used in children. Manufacturers could defer studies to a post-approval commitment, but the obligation became enforceable.

Outcome

Short Term

New drug approvals began routinely carrying pediatric study requirements, often as post-marketing commitments tied to specific deadlines.

Long Term

Hundreds of products have since had labels updated to add pediatric data, gradually closing gaps where children received off-label prescribing of adult drugs.

Why It's Relevant Today

ASCENIV's 2026 pediatric expansion is a direct product of this regulatory framework: the 2019 approval included a pediatric study commitment that this supplemental application now fulfills.

BIVIGAM pediatric approval (2018)

May 2018

What Happened

ADMA's other intravenous immune globulin product, BIVIGAM, received FDA approval that already included pediatric patients aged 2 and older—a different regulatory path than ASCENIV's adolescent-first approval one year later.

Outcome

Short Term

ADMA had a pediatric-eligible IVIG in its portfolio while ASCENIV remained restricted to adolescents and adults.

Long Term

The split labels created a portfolio gap that the 2026 ASCENIV expansion now closes, allowing ADMA to position both products for pediatric immunologists.

Why It's Relevant Today

Shows that pediatric label coverage is a competitive feature within ADMA's own product line, not just across rival manufacturers.

Original ASCENIV approval (April 2019)

April 2019

What Happened

The FDA approved ASCENIV for primary humoral immunodeficiency in adults and adolescents based on a pivotal study of 59 patients treated for 12 months, with a requirement to subsequently study children aged 2 to 11.

Outcome

Short Term

Commercial launch followed in late 2019, with ASCENIV positioned as a specialty IVIG differentiated by RSV-antibody-enriched plasma.

Long Term

ASCENIV grew into ADMA's top revenue driver, reaching $363 million in 2025 sales—creating commercial incentive to complete the pediatric study and expand the addressable patient population.

Why It's Relevant Today

The current event is the closing chapter of the regulatory commitment opened seven years ago; it also unlocks the pediatric portion of an already fast-growing franchise.

Sources

(7)
+1
GlobeNewswire Conexiant Pediatrics GuruFocus U.S. Food and Drug Administration Pharmacy Times Immune Deficiency Foundation GlobeNewswire